Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBORN: Cisplatin + irinotecan plus durvalumab for untreated extensive-stage small cell lung cancer
jRCT2051200125Phase 2Completed
- Start
- May 2021
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, cisplatin and irinotecan in small cell lung cancer (SCLC). Primary endpoint: Proportion of 12-month progression-free survival (central imaging review). Started May 2021; status: completed.
02
Drugs
durvalumabcisplatinirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2051200125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200125.